keyword
MENU ▼
Read by QxMD icon Read
search

Lisdexamfetamine

keyword
https://www.readbyqxmd.com/read/29258368/lisdexamfetamine-chemistry-pharmacodynamics-pharmacokinetics-and-clinical-efficacy-safety-and-tolerability-in-the-treatment-of-binge-eating-disorder
#1
Kristen Ward, Leslie Citrome
The indications for lisdexamfetamine (LDX), a central nervous system stimulant, were recently expanded to include treatment of moderate to severe binge eating disorder (BED). Areas covered: This review aims to describe the chemistry and pharmacology of LDX, as well as the clinical trials investigating the efficacy and safety of this medication for the management of BED. Expert opinion: LDX is the first medication with United States Food and Drug Administration approval for the treatment of BED. It is an inactive prodrug of d-amphetamine that extends the half-life of d-amphetamine to allow for once daily dosing...
January 4, 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29186993/medication-use-in-adults-with-attention-deficit-hyperactivity-disorder-in-a-commercially-insured-population-in-the-united-states
#2
Zhou Zhou, Zheng-Yi Zhou, Sneha S Kelkar, Vanja Sikirica, Jipan Xie, Regina Grebla
OBJECTIVE: To examine real-world prescription medication usage among commercially-insured adults with attention deficit/hyperactivity disorder (ADHD) in the US. METHODS: Adults with ADHD who received ≥1 ADHD medication during 2013 were identified from a large US claims database. Combination therapy was defined as an overlap of ≥30 days between the index (first treatment ≥30 days in 2013) and another medication(s). Patients were classified into six groups: long-acting (LA) monotherapy, short-acting (SA) monotherapy, LA + LA, SA + SA, LA + SA, and >2 therapies...
December 8, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29180967/efficacy-and-tolerability-of-different-interventions-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder
#3
Ruiling Luan, Zhiling Mu, Fang Yue, Shaoying He
Background: Our study is an analysis of multiple publications involving assessing the comparable efficacy and tolerability of six interventions, which are lisdexamfetamine dimesylate (LDX), atomoxetine (ATX), methylphenidate (MPH), clonidine hydrochloride (CLON), guanfacine extended release (GXR), and bupropion, for young patients (6-18 years old) suffering from attention deficit hyperactivity disorder (ADHD). Methods: A conventional meta-analysis (MA) was performed to give direct comparisons and a network meta-analysis (NMA) was used to show the combination of direct and indirect evidence...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29134566/lisdexamfetamine-a-review-in-binge-eating-disorder
#4
Young-A Heo, Sean T Duggan
Oral lisdexamfetamine dimesylate (Vyvanse®; lisdexamfetamine), a prodrug of dextroamfetamine, is currently the only drug to be approved in the USA for the treatment of moderate to severe binge eating disorder (BED) in adult patients. Its approval was based on the results of two pivotal short-term (12 weeks) phase III studies, which showed a significantly greater reduction in binge eating days/week at the end of the study with lisdexamfetamine 50-70 mg/day than with placebo. The findings of these studies have been supported and extended by the results of longer-term (≤ 52 weeks) phase III studies, including one with a randomized 26-week withdrawal phase, which showed that lisdexamfetamine markedly reduced the risk of BED relapse relative to placebo...
November 2017: CNS Drugs
https://www.readbyqxmd.com/read/29113456/a-systematic-review-of-cost-effectiveness-studies-of-prevention-and-treatment-for-eating-disorders
#5
Long Khanh-Dao Le, Phillipa Hay, Cathrine Mihalopoulos
BACKGROUND: Eating disorders are serious mental disorders and are associated with substantial economic and social burden. The aim of this study is to undertake a systematic review of the cost-effectiveness studies of both preventive and treatment interventions for eating disorder. METHOD: Electronic databases (including the Cochrane Controlled Trial Register, MEDLINE, PsycINFO, Academic Search Complete, Global Health, CINAHL complete, Health Business Elite, Econlit, Health Policy Reference Center and ERIC) were searched for published cost-effectiveness studies of eating disorder prevention and treatment including papers published up to January 2017...
November 1, 2017: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/29053927/safety-of-pharmacotherapy-options-for-bulimia-nervosa-and-binge-eating-disorder
#6
Nicholas T Bello, Bryn L Yeomans
Eating disorders represent a set of psychiatric illnesses with lifelong complications and high relapse rates. Individuals with eating disorders are often stigmatized and clinicians have a limited set of treatments options. Pharmacotherapy has the potential to improve long term compliance and patient commitment to treatment for eating disorders. Areas Covered: This review will examine the efficacy and safety profile of the FDA-approved medications for the treatment of bulimia nervosa (BN) and binge eating disorder (BED)...
October 20, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29044551/disordered-eating-and-obesity-associations-between-binge-eating-disorder-night-eating-syndrome-and-weight-related-comorbidities
#7
REVIEW
Courtney McCuen-Wurst, Madelyn Ruggieri, Kelly C Allison
Binge-eating disorder (BED) and night-eating syndrome (NES) are two forms of disordered eating associated with overweight and obesity. While these disorders also occur in nonobese persons, they seem to be associated with weight gain over time and higher risk of diabetes and other metabolic dysfunction. BED and NES are also associated with higher risk of psychopathology, including mood, anxiety, and sleep problems, than those of similar weight status without disordered eating. Treatments are available, including cognitive behavior therapy (CBT), interpersonal psychotherapy, lisdexamfetamine, and selective serotonin reuptake inhibitors (SSRIs) for BED; and CBT, SSRIs, progressive muscle relaxation, and bright light therapy for NES...
October 16, 2017: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/29028590/efficacy-and-tolerability-of-lisdexamfetamine-as-an-antidepressant-augmentation-strategy-a-meta-analysis-of-randomized-controlled-trials
#8
Peter Giacobbe, Uros Rakita, Raymond Lam, Roumen Milev, Sidney H Kennedy, Roger S McIntyre
BACKGROUND: Psychostimulants have been used in the treatment of depression, with mixed results. This meta-analysis examines the efficacy and tolerability of the stimulant Lisdexamfetamine (LDX) as an add-on strategy in those with MDD who have failed to respond to an antidepressant. METHOD: Randomized control trials were identified and extracted from Pubmed; Web of Science; PsychINFO; and Cochrane Library. The efficacy of LDX was evaluated using Hedges' g and Odds Ratio, whereas Risk Difference was used to assess the safety and tolerability of LDX...
January 15, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28980198/randomized-double-blind-placebo-controlled-acute-comparator-trials-of-lisdexamfetamine-and-extended-release-methylphenidate-in-adolescents-with-attention-deficit-hyperactivity-disorder
#9
Jeffrey H Newcorn, Peter Nagy, Ann C Childress, Glen Frick, Brian Yan, Steven Pliszka
BACKGROUND: Psychostimulants are considered first-line pharmacotherapy for youth with attention-deficit/hyperactivity disorder (ADHD), but questions remain regarding the comparative efficacy of amphetamine- and methylphenidate-based agents. OBJECTIVE: Our objective was to describe two acute randomized, double-blind, placebo-controlled, head-to-head studies of lisdexamfetamine dimesylate (LDX) and osmotic-release oral system methylphenidate (OROS-MPH) in adolescents with ADHD...
October 4, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28936175/pharmacokinetics-and-pharmacodynamics-of-lisdexamfetamine-compared-with-d-amphetamine-in-healthy-subjects
#10
Patrick C Dolder, Petra Strajhar, Patrick Vizeli, Felix Hammann, Alex Odermatt, Matthias E Liechti
Rationale: Lisdexamfetamine is a prodrug of D-amphetamine used for the treatment of attention-deficit/hyperactivity disorder (ADHD). Lisdexamfetamine is thought to have a prolonged pharmacokinetic profile compared with oral D-amphetamine, possibly associated with lower drug liking and a lower risk of oral misuse. However, differences in the pharmacokinetics and pharmacodynamics of lisdexamfetamine and D-amphetamine have not been directly compared. Methods: Equimolar doses of D-amphetamine (40 mg) and lisdexamfetamine (100 mg), and placebo were administered in 24 healthy subjects in a randomized, double-blind, placebo-controlled, cross-over study...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28933969/psychopharmacological-advances-in-eating-disorders
#11
REVIEW
Hubertus Himmerich, Janet Treasure
Anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorder (BED) are the primary eating disorders (EDs). The only psychopharmacological treatment options for EDs with approval in some countries include fluoxetine for BN and lisdexamfetamine for BED. Given the high comorbidity and genetic correlations with other psychiatric disorders, it seems possible that novel medications for these conditions might also be effective in EDs. Areas covered: The current scientific literature has increased our understanding of how medication could be beneficial for patients with EDs on a molecular, functional and behavioral level...
January 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28857719/a-randomized-double-blind-placebo-controlled-dose-ranging-study-of-lisdexamfetamine-dimesylate-augmentation-for-major-depressive-disorder-in-adults-with-inadequate-response-to-antidepressant-therapy
#12
Cynthia Richards, Dan V Iosifescu, Rajnish Mago, Elias Sarkis, James Reynolds, Brooke Geibel, Matthew Dauphin
BACKGROUND: This randomized, double-blind, placebo-controlled study evaluated dose-response relationships of lisdexamfetamine dimesylate when used as augmentation for major depressive disorder in individuals exhibiting inadequate responses to antidepressant monotherapy. METHODS: Eligible adults (18-65 years) were assigned to antidepressant monotherapy (escitalopram or venlafaxine extended-release) plus lisdexamfetamine dimesylate-matching placebo during an eight-week single-blind lead-in phase...
September 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28855799/review-of-lisdexamfetamine-dimesylate-in-adults-with-attention-deficit-hyperactivity-disorder
#13
REVIEW
Jadwiga Najib, Dexter Wimer, Julie Zeng, Kristina W Lam, Natalya Romanyak, Eva Paige Morgan, Anu Thadavila
Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant used for the treatment of attention-deficit/hyperactivity disorder (ADHD) dosed once daily. Due to its long-acting properties, LDX remains pharmacologically inactive until an enzymatic process predominantly associated with red blood cells converts it to the active ingredient, d-amphetamine and the amino acid lysine. The efficacy of LDX over placebo has been demonstrated in several studies in adults with moderate to severe ADHD with significant improvements noted in ADHD rating scales, Clinical Global Improvement scores, and assessments of executive function, for all doses of LDX (30-70 mg daily)...
2017: Journal of Central Nervous System Disease
https://www.readbyqxmd.com/read/28837827/pharmacotherapy-of-emotional-dysregulation-in-adults-with-adhd-a-systematic-review-and-meta-analysis
#14
REVIEW
Francesca Lenzi, Samuele Cortese, Joseph Harris, Gabriele Masi
Emotional dysregulation (ED) is a dysfunction in modifying an emotional state in an adaptive and goal oriented way, with excitability, ease anger, and mood lability. It is present in up to 70% of adults with ADHD, regardless of other comorbidities, and substantially worsens the psychosocial outcomes of the disorder. Besides fronto-parietal circuits mediating top-down control, brain regions involved in bottom-up processes (e.g., amygdala, orbitofrontal cortex, and ventral striatum) are implicated in ED. We performed a systematic review/meta-analysis of double-blind randomized controlled trials of ADHD medications to assess their effects on ED in adults with ADHD...
August 25, 2017: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/28836895/correlations-between-clinical-trial-outcomes-based-on-symptoms-functional-impairments-and-quality-of-life-in-children-and-adolescents-with-adhd
#15
David R Coghill, Alain Joseph, Vanja Sikirica, Mark Kosinski, Caleb Bliss, Michael Huss
OBJECTIVE: To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional impairments, and health-related quality of life in children and adolescents with ADHD. METHOD: Pearson correlation coefficients were calculated post hoc for changes from baseline to endpoint in outcomes of one randomized, placebo- and active-controlled trial of lisdexamfetamine (osmotic-release methylphenidate reference) and one of guanfacine extended-release (atomoxetine reference)...
August 1, 2017: Journal of Attention Disorders
https://www.readbyqxmd.com/read/28806268/pharmacotherapy-of-eating-disorders
#16
Haley Davis, Evelyn Attia
PURPOSE OF REVIEW: Medications are commonly prescribed in the treatment of eating disorders. In this review, we discuss relevant medications used for the treatment of bulimia nervosa, binge eating disorder (BED), and anorexia nervosa. We focus on recent research developments, where applicable, in addition to discussing important findings from older studies to provide a complete synopsis of the current evidence base for eating disorder treatment using pharmacologic agents. RECENT FINDINGS: Medications are generally useful for patients with bulimia nervosa and BED...
November 2017: Current Opinion in Psychiatry
https://www.readbyqxmd.com/read/28700805/efficacy-of-lisdexamfetamine-in-adults-with-moderate-to-severe-binge-eating-disorder-a-randomized-clinical-trial
#17
RANDOMIZED CONTROLLED TRIAL
James I Hudson, Susan L McElroy, M Celeste Ferreira-Cornwell, Jana Radewonuk, Maria Gasior
Importance: The ability of pharmacotherapies to prevent relapse and maintain efficacy with long-term treatment in psychiatric conditions is important. Objective: To assess lisdexamfetamine dimesylate maintenance of efficacy in adults with moderate to severe binge-eating disorder. Design, Setting, and Participants: A multinational, phase 3, double-blind, placebo-controlled, randomized withdrawal study including 418 participants was conducted at 49 clinical research study sites from January 27, 2014, to April 8, 2015...
September 1, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28667569/long-term-safety-and-efficacy-of-lisdexamfetamine-dimesylate-in-children-and-adolescents-with-adhd-a-phase-iv-2-year-open-label-study-in-europe
#18
David R Coghill, Tobias Banaschewski, Peter Nagy, Isabel Hernández Otero, César Soutullo, Brian Yan, Beatriz Caballero, Alessandro Zuddas
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is increasingly recognized as a persistent disorder requiring long-term management. OBJECTIVES: Our objective was to evaluate the 2-year safety and efficacy of lisdexamfetamine dimesylate (LDX) in children and adolescents with ADHD. METHODS: Participants (aged 6-17 years) with ADHD received open-label, dose-optimized LDX 30, 50, or 70 mg/day for 104 weeks. Safety monitoring included treatment-emergent adverse events (TEAEs), vital signs, electrocardiography, and growth...
July 2017: CNS Drugs
https://www.readbyqxmd.com/read/28651185/treatment-of-neurocognitive-symptoms-in-unipolar-depression-a-systematic-review-and-future-perspectives
#19
REVIEW
E Salagre, B Solé, Y Tomioka, B S Fernandes, D Hidalgo-Mazzei, M Garriga, E Jimenez, J Sanchez-Moreno, E Vieta, I Grande
BACKGROUND: Cognitive symptoms in Major Depressive Disorder (MDD) are persistent and commonly entail neurocognitive impairment and a decline in quality of life. This systematic review gathers the current scientific evidence on therapeutic strategies for neuropsychological impairment in MDD. METHOD: A systematic search on PubMed, PsycINFO and Clinicaltrials.gov was carried out on December 2016 according to PRISMA using Boolean terms to identify interventions for the treatment of cognitive dysfunction in MDD...
October 15, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28590365/the-efficacy-of-psychostimulants-in-major-depressive-episodes-a-systematic-review-and-meta-analysis
#20
Roger S McIntyre, Yena Lee, Aileen J Zhou, Joshua D Rosenblat, Evyn M Peters, Raymond W Lam, Sidney H Kennedy, Carola Rong, Jeanette M Jerrell
BACKGROUND: Psychostimulants are frequently prescribed off-label for adults with major depressive disorder or bipolar disorder. The frequent and increasing usage of stimulants in mood disorders warrants a careful appraisal of the efficacy of this class of agents. Herein, we aim to estimate the efficacy of psychostimulants in adults with unipolar or bipolar depression. METHODS: The PubMed/Medline database was searched from inception to January 16, 2016 for randomized, placebo-controlled clinical trials investigating the antidepressant efficacy of psychostimulants in the treatment of adults with unipolar or bipolar depression...
August 2017: Journal of Clinical Psychopharmacology
keyword
keyword
7577
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"